7,129 Johnson & Johnson $JNJ Shares Sold by Smith Chas P & Associates PA Cpas

Smith Chas P & Associates PA Cpas decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.9% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 238,267 shares of the company’s stock after selling 7,129 shares during the period. Johnson & Johnson makes up about 3.0% of Smith Chas P & Associates PA Cpas’ portfolio, making the stock its 8th biggest holding. Smith Chas P & Associates PA Cpas’ holdings in Johnson & Johnson were worth $60,891,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Cypress Wealth Services LLC lifted its holdings in shares of Johnson & Johnson by 0.4% in the third quarter. Cypress Wealth Services LLC now owns 10,618 shares of the company’s stock worth $2,705,000 after acquiring an additional 39 shares during the last quarter. Kooman & Associates boosted its stake in shares of Johnson & Johnson by 5.3% in the 3rd quarter. Kooman & Associates now owns 1,051 shares of the company’s stock valued at $278,000 after purchasing an additional 53 shares in the last quarter. Diligent Investors LLC grew its holdings in shares of Johnson & Johnson by 1.3% during the 3rd quarter. Diligent Investors LLC now owns 11,079 shares of the company’s stock valued at $2,933,000 after purchasing an additional 147 shares during the last quarter. Cardinal Capital Management grew its holdings in shares of Johnson & Johnson by 1.0% during the 3rd quarter. Cardinal Capital Management now owns 115,964 shares of the company’s stock valued at $30,700,000 after purchasing an additional 1,151 shares during the last quarter. Finally, Oakmont Investment Advisors Inc. increased its position in Johnson & Johnson by 1.0% during the 3rd quarter. Oakmont Investment Advisors Inc. now owns 7,670 shares of the company’s stock worth $2,030,000 after purchasing an additional 76 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The United Kingdom approved J&J’s oral psoriasis treatment, expanding the company’s commercial opportunity in a major market and strengthening its immunology pipeline. UK approves J&J’s oral psoriasis pill
• Positive Sentiment: J&J reported first real-world data for its VARIPULSE Pro platform and 12-month outcomes for the OMNYPULSE platform in atrial-fibrillation treatment. The results could support adoption of its MedTech portfolio and help offset weakness in other device businesses. J&J reports VARIPULSE Pro and OMNYPULSE data
• Positive Sentiment: J&J has benefited from investor rotation into defensive healthcare and consumer-staples companies amid broader large-cap weakness, reinforcing demand for its relatively stable earnings and dividend profile. Defensive stocks attract buyers
• Neutral Sentiment: J&J’s implied fair value was raised from $270.59 to $279.41 per share, but analyst views remain divided. Supporters cite earnings resilience and the drug pipeline, while others point to valuation, MedTech execution risk and possible dilution from recent deals. J&J fair value adjustment
• Negative Sentiment: A proposed combination involving J&J’s orthopedics business and Smith & Nephew reportedly collapsed over a leadership dispute. The development removes potential strategic benefits and may raise questions about execution, although Smith & Nephew declined to comment. Orthopedics merger reportedly collapsed
• Negative Sentiment: J&J reclaimed its 50-day moving average, but falling earnings estimates, a premium valuation and weakness in MedTech are limiting the bullish technical signal. Erste Group also downgraded the shares to “Hold,” adding to near-term investor caution. J&J stock outlook and valuation concerns

Insider Buying and Selling

In related news, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 64,515 shares of company stock valued at $17,271,766 over the last 90 days. 0.16% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on JNJ. Evercore set a $300.00 target price on shares of Johnson & Johnson in a research report on Tuesday. Argus set a $300.00 price target on shares of Johnson & Johnson in a report on Wednesday, July 29th. Morgan Stanley dropped their price target on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a research note on Thursday, October 15th. TD Cowen reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday. Finally, Bank of America restated a “neutral” rating and set a $278.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, September 29th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $275.92.

Johnson & Johnson Stock Down 1.3%

Shares of NYSE JNJ opened at $264.13 on Friday. The company has a 50 day simple moving average of $265.64 and a 200 day simple moving average of $250.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.81. Johnson & Johnson has a 1 year low of $184.66 and a 1 year high of $281.07. The firm has a market cap of $635.85 billion, a PE ratio of 40.02, a price-to-earnings-growth ratio of 2.61 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. During the same period in the previous year, the firm posted $2.80 EPS. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, research analysts forecast that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. Johnson & Johnson’s payout ratio is currently 81.21%.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.